Skip to content
RNAWiki

Granisetron

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Granisetron does in the body

Granisetron hydrochloride injection, is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.

From the FDA-approved label: Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1 ; 5-HT 1A ; 5-HT 1B/C ; 5-HT 2 ; for alpha 1 -, alpha 2 - or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1 ; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy-induced vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT 3 receptors. This evokes vagal afferent discharge and may induce vomiting.

Why people take it. Granisetron hydrochloride injection, is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · WZG3J2MCOL · read 2026-08-29

  • Its recorded molecular formula is C18H24N4O•HCl, weighing 348.9.

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-30

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 174 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Adherence to PONV Guidelines

The study did not show it

Who was studied
NCT02625181
How many people
27034
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1

The study did not show it

Who was studied
NCT00343460
How many people
1428
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

No Emetic Episodes and No Rescue Medication

The study did not show it

Who was studied
NCT01500226
How many people
1369
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Complete response (CR: no emetic episodes and no rescue medication) rate in acute and delayed nausea and vomiting

The study did not show it

Who was studied
NCT00359567
How many people
1140
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

complete response

The study did not show it

Who was studied
NCT05841849
How many people
1028
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Home Record: Severity of Delayed Nausea

The study did not show it

Who was studied
NCT00475085
How many people
1021
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “Safety and effectiveness in pediatric patients under 2 years of age have not been established.”

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-30

  • On older people, the label states: “Clinical studies of granisetron hydrochloride injection did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.”

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-30

  • On people who are pregnant, the label states: “There are, however, no adequate and well-controlled studies in pregnant women.”

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-30

  • On people who are breastfeeding, the label states: “It is not known whether granisetron is excreted in human milk.”

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Sold as tablet, injectable, solution, film, extended release, given by the oral, injection, subcutaneous route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 29 products list this as an active ingredient in the United States drug directory. 29 of them contain it and nothing else.

    FDA National Drug Code directory · 14778-0303 · read 2026-08-29

  • They are sold as injection, injection, solution, patch, powder, solution and tablet, taken intravenous, oral, subcutaneous and transdermal.

    FDA National Drug Code directory · 14778-0303 · read 2026-08-29

  • The regulator's established pharmacologic class for it is serotonin 3 receptor antagonists [moa] and serotonin-3 receptor antagonist [epc].

    FDA National Drug Code directory · 14778-0303 · read 2026-08-29

  • 10 published labels name it as an active ingredient. 10 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-29

  • Granisetron Hydrochloride is intravenous at 3 DOSAGE FORMS AND STRENGTHS Single-Dose Vials for Injection: 1 mg/mL Multiple-Dose Vials for Injection: 4 mg/4 mL Injection 1 mg/mL (free base)., recorded as fda label in effect 2025-04-24 in the United States.

    US prescribing information · 783e9d68-2371-4fd4-8d7a-a5e36f8718d0 · read 2026-08-30

  • Recorded price in US: 1.27078 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 7 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

  • Which of the trials of Granisetron studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Granisetron are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 10 documents were read for this substance.

    RNAWiki source record

  • 10 of them state the same proteinBinding, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
WZG3J2MCOL
RxNorm concept
825003

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Not passed

    Safety mode resolved

    No register row and no identity class settled the question.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 53 approved applications cover products containing this substance. The earliest was NDA020239, approved 19931229 to ROCHE.

    Drugs@FDA application register · NDA020239 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA020239 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 20051030.

    FDA National Drug Code directory · 14778-0303 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (8)

On the Granisetron label: indicated for what?

"SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is a serotonin-3…": indications and usage on Granisetron's label. DailyMed label · f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 · 2026-04-30

78 registered trials of Granisetron — at which phases?

Registered studies posting no result
57 of 78

78 registered studies of Granisetron: 24 phase3, 18 phase2, 13 phase1, 13 phase4, 11 na, 1 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01

507 with a PubMed record

Show the evidence
  • phase3
    24
  • phase2
    18
  • phase1
    13
  • phase4
    13
  • na
    11
  • na or unstated
    1
6 more recorded rows
  • completed
    53
  • unknown
    14
  • withdrawn
    5
  • terminated
    3
  • active not recruiting
    2
  • not yet recruiting
    1

recorded 2026-09-01 · last checked 2026-09-04

8 of Granisetron's trials stopped: futility/efficacy, accrual/recruitment, funding/business, other?

futility/efficacy (1), accrual/recruitment (2), funding/business (2) and other (3): Granisetron's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Study was stopped due to inadequate accrual."; 8 of 78 registered studies

Show the evidence

Trial

  • NCT01183481
    terminated; "Study was stopped due to inadequate accrual."
  • NCT01275664
    terminated; "Study terminated due to no patient population available"
  • NCT01596413
    withdrawn; "The company currently does not have plans to conduct this study"
  • NCT01596426
    withdrawn; "The company currently does not have plans to conduct this study"
  • NCT01649258
    terminated; "Lack of Efficacy"
  • NCT01843868
    withdrawn; "Study halted prematurely, prior to enrollment of first participant due to protracted logistical and subsequent funding matters."
2 further recorded trials
  • NCT01952886
    withdrawn; "Lack of approval and funding from company"
  • NCT04501211
    withdrawn; "Abandoned due to limited resources"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Granisetron used Granisetron hydrochloride 1 mg tablets — over how long?

Human studies of Granisetron used "Granisetron hydrochloride 1 mg tablets". ClinicalTrials.gov · 2026-09-01

7 recorded entries; human; IV; also "Kytril® 1 mg tablets", "Kytril 1mg (IV injection)", "Kytril 1mg (Tablet)"

Show the evidence

human

  • NCT00834522
    Granisetron hydrochloride 1 mg tablets
  • NCT00834522
    Kytril® 1 mg tablets
  • NCT02563951
    IV; Kytril 1mg (IV injection)
  • NCT02563951
    Kytril 1mg (Tablet)
  • NCT02588547
    IV; Kytril ampule 3mg/3ml IV (Roche)
  • NCT03017391
    Granisetron 2Mg Tablet
1 more recorded row
  • human NCT03091881
    Granisetron 0.1 MG/ML

recorded 2026-09-01 · last checked 2026-09-04

Granisetron's half-life is 24 hours — which schedules were studied?

24 hours, the half-life Granisetron's label states: "Elimination Metabolism: Following a single 10 mg subcutaneous injection of SUSTOL, the terminal elimination half-life of granisetron was approximately 24 hours and was comparable between healthy subjects and patients." DailyMed label · f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 · 2026-04-30

tmax 24 hours.

Show the evidence
  • half life pharmacokinetics
    24 hours; Elimination Metabolism: Following a single 10 mg subcutaneous injection of SUSTOL, the terminal elimination half-life of granisetron was approximately 24 hours and was comparable between healthy subjects and patients.
  • tmax pharmacokinetics
    24 hours; Injection Site Location Abdomen N=113 Upper Arm N=113 C max (ng/mL) 9.8 ± 4.8 10.8 ± 4.6 T max (hours) [range] 12 [1 to 144] 11 [1 to 120] AUC inf , ng.h/mL 680 ± 362 720 ± 366 In patients, peak plasma granisetron concentrations were delayed compared to healthy subjects with a median T max of approximately 24 hours.
  • metabolism pharmacokinetics
    Metabolism Published data suggests that granisetron is metabolized by CYP1A1 and CYP3A4.

recorded 2026-04-30 · last checked 2026-09-04

Which 32 trials of Granisetron posted no result?

Posted no result
32 of 32 completed trials
Registrations
NCT00003213, NCT00003817, NCT00020657, NCT00618111, NCT00618254 and NCT00450853, and 26 more
Completion dates
oldest 1999-08; newest 2023-01-30
Show the evidence

Trial

  • NCT00003213
    1999-08
  • NCT00003817
    2001-07
  • NCT00020657
    2004-10
  • NCT00618111
    2005-04
  • NCT00618254
    2005-04
  • NCT00450853
    2005-11
14 further recorded trials
  • NCT00273468
    2006-10
  • NCT00503386
    2006-10
  • NCT01352130
    2007-04
  • NCT00359567
    2007-08
  • NCT00511823
    2007-09-21
  • NCT00272285
    2008-03
  • NCT00873197
    2009-05
  • NCT00415103
    2009-09
  • NCT00868764
    2009-09
  • NCT00890565
    2009-09
  • NCT01937156
    2014-02
  • NCT01909856
    2014-06
  • NCT02230371
    2014-12
  • NCT02563951
    2015-12

At the median, Granisetron's trials enrolled 92 people — anything larger?

Median enrolment
92
Largest enrolment
27034
Registered trials counted
75

Granisetron and CYP1A1, CYP3A4 and CYTOCHROME P-450: shared by which compounds?

CYP1A1, CYP3A4 and CYTOCHROME P-450 appear in Granisetron's recorded interaction sentences, 8 in all. DailyMed label · f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 · 2026-04-30

CYP1A1, CYP1A1, CYP3A4, CYP3A4; 4 shared nodes; pharmacokinetics, clinical_pharmacology

Show the evidence

Interaction statement

  • pharmacokinetics
    Metabolism Published data suggests that granisetron is metabolized by CYP1A1 and CYP3A4.
  • pharmacokinetics
    Drug Interaction Studies Effect of Other Drugs on Granisetron Granisetron is metabolized by the hepatic cytochrome P-450 drug-metabolizing enzymes CYP1A1 and CYP3A4.
  • pharmacokinetics
    Inducers or inhibitors of CYP1A1 and CYP3A4 enzymes may affect the clearance and half-life of granisetron.
  • pharmacokinetics
    Effect of Granisetron on Other Drugs Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system in vitro .
  • pharmacokinetics
    In addition, the in vitro activity of the cytochrome P-450 subfamily 3A4, which is involved in the metabolism of some narcotic analgesics, is not modified by granisetron.
  • clinical_pharmacology
    Metabolism Published data suggests that granisetron is metabolized by CYP1A1 and CYP3A4.
2 more recorded rows
  • Interaction statement clinical_pharmacology
    Drug Interaction Studies Effect of Other Drugs on Granisetron Granisetron is metabolized by the hepatic cytochrome P-450 drug-metabolizing enzymes CYP1A1 and CYP3A4.
  • Interaction statement clinical_pharmacology
    Inducers or inhibitors of CYP1A1 and CYP3A4 enzymes may affect the clearance and half-life of granisetron.

CYP1A1

  • Omadacycline, Pivmecillinam, Remdesivir, Triclabendazole, Erlosamide, Carglumic acid, Ceftaroline fosamil, SOLIFENACIN, (1R,3'R)-
  • Omadacycline, Pivmecillinam, Remdesivir, Triclabendazole, Erlosamide, Carglumic acid, Ceftaroline fosamil, SOLIFENACIN, (1R,3'R)-

CYP3A4

  • FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium
  • FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium

recorded 2026-04-30 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1290003
CAS number
109889-09-0
RxCUI
825003
InChIKey
MFWNKCLOYSRHCJ-BTTYYORXSA-N
Also called
CHEMBL1290003, 1-Methyl-N-(9-methyl-endo-9-azabicyclo[3.3.1]non-3-yl)-1H-indazole-3-carboxamide, 1H-INDAZOLE-3-CARBOXAMIDE, 1-METHYL-N-(9-METHYL-9-AZABICYCLO(3.3.1)NON-3-YL)-, ENDO-, GRANISETRON [JAN], GRANISETRON [MI], GRANISETRON [ORANGE BOOK], GRANISETRON [USAN], GRANISETRON [USP MONOGRAPH]
Salt form
Granisetron Hydrochloride, Granisetron Hydrochloride Preservative Free, Granisetron Hydrochloride / Kytril / Granisetron Hydrochloride Preservative Free / Sustol / Sancuso / Granisol
Trade name
Kytril, Sustol, Sancuso, Granisol
Development code
APF-530, APF530, BRL 43694
Sources (5)

Sources

  • CLINICALTRIALS_SNAPSHOT K1:WZG3J2MCOL ·
  • ClinicalTrials.gov clinicaltrials.gov ·
  • drugsfda+ema drugsfda+ema ·
  • DailyMed label f7c7ffdd-8270-4030-bc1e-a1cb28a6de56 ·
  • Drugs@FDA K1:WZG3J2MCOL ·

ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 5 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.